BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15180540)

  • 21. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
    Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
    Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
    Liu T; Huang B; Zhan P; De Clercq E; Liu X
    Eur J Med Chem; 2014 Oct; 86():481-90. PubMed ID: 25203778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
    Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
    Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.
    Anang S; Zhang S; Fritschi C; Chiu T-J; Yang D; Smith Iii AB; Madani N; Sodroski J
    J Virol; 2023 Nov; 97(11):e0117123. PubMed ID: 37888980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    Moore JP
    AIDS; 1990 Apr; 4(4):297-305. PubMed ID: 2190604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.
    Wensel D; Sun Y; Li Z; Zhang S; Picarillo C; McDonagh T; Fabrizio D; Cockett M; Krystal M; Davis J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.
    Langley DR; Kimura SR; Sivaprakasam P; Zhou N; Dicker I; McAuliffe B; Wang T; Kadow JF; Meanwell NA; Krystal M
    Proteins; 2015 Feb; 83(2):331-50. PubMed ID: 25401969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors.
    Zaitseva M; Peden K; Golding H
    Biochim Biophys Acta; 2003 Jul; 1614(1):51-61. PubMed ID: 12873765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry.
    Da LT; Quan JM; Wu YD
    Proteins; 2011 Jun; 79(6):1810-9. PubMed ID: 21465559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
    Wang T; Zhang Z; Wallace OB; Deshpande M; Fang H; Yang Z; Zadjura LM; Tweedie DL; Huang S; Zhao F; Ranadive S; Robinson BS; Gong YF; Ricarrdi K; Spicer TP; Deminie C; Rose R; Wang HG; Blair WS; Shi PY; Lin PF; Colonno RJ; Meanwell NA
    J Med Chem; 2003 Sep; 46(20):4236-9. PubMed ID: 13678401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
    Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120.
    Fontenot JD; Tan X; Phillips DM
    AIDS; 1998 Aug; 12(12):1413-8. PubMed ID: 9727561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors.
    Sivan SK; Vangala R; Manga V
    Bioorg Med Chem; 2013 Aug; 21(15):4591-9. PubMed ID: 23777826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent anti-HIV (type 1 and type 2) activity of polyoxometalates: structure-activity relationship and mechanism of action.
    Witvrouw M; Weigold H; Pannecouque C; Schols D; De Clercq E; Holan G
    J Med Chem; 2000 Mar; 43(5):778-83. PubMed ID: 10715146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.